Shay Capital’s Krystal Biotech KRYS Stock Holding History

Shay Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,500	Closed	-$893K	–	464
2025 Q2	$893K	Buy	+6,500	New	+$955K	0.1%	126

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital's KRYS Position: Q3 2025 in Review

Shay Capital sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 6,500 shares — an estimated $893K sold.

Shay Capital first reported a position in KRYS in Q2 2025 and held it in 1 quarter. The position peaked at $893K in Q2 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

Shay Capital reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
Shay Capital sold 6,500 Krystal Biotech shares in Q3 2025, an estimated $893K.
Shay Capital first reported a position in Krystal Biotech in Q2 2025 and held it in 1 quarter.
Shay Capital's Krystal Biotech position peaked at $893K in Q2 2025.
284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Shay Capital's 13F filing for Q3 2025, filed 14 Nov 2025.